Long-term liposteroid therapy for idiopathic pulmonary hemosiderosis

Takehiko Doi, Shoichi Ohga, masataka ishimura, Hidetoshi Takada, Kanako Ishii, Kenji Ihara, Hideyuki Nagai, Toshiro Hara

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Control of refractory bleeding in idiopathic pulmonary hemosiderosis (IPH) is challenging. Based on the effect of liposteroid (dexamethasone palmitate) for acute bleeding in two reported cases, the long-term utility was assessed in all nine IPH children (including the first two cases) treated in a tertiary center for 20 years. The median at disease onset was 2.3 years (range, 1.2 to 8.6). All had life-threatening and/or repetitive bleeding on prednisolone (PSL) therapy. Liposteroid was intravenously infused at 0.8 mg/kg/day for three consecutive days at the time of acute bleeding. Single infusion was followed by a longer interval from weekly to monthly accompanied by low-dose PSL (less than 0.3 mg/kg/day). Monthly infusion as maintenance therapy was continued for prophylaxis of bleeding. Treatment outcomes were retrospectively analyzed. During the observation period of a median of 11.0 years (range 2.4-16.9 years), no one died. Five patients were weaned and the other one was being weaned from liposteroid for the cure or long remission (median, 5.5 years). Three others were on liposteroid therapy because of active disease. Neither patient had respiratory symptoms, although three showed subnormal %vital capacity. Serum levels of KL-6 and ferritin were normal in all and all but one patient(s), respectively. Four patients (three on liposteroid therapy) showed low bone mineral density. There were no obese patients. Height SD score did not significantly decrease except for one patient. Conclusion: The liposteroid therapy might improve the survival of IPH patients with reducing the adverse effects of steroids, although prospective control studies are needed.

Original languageEnglish
Pages (from-to)1475-1481
Number of pages7
JournalEuropean Journal of Pediatrics
Volume172
Issue number11
DOIs
Publication statusPublished - Jan 1 2013

Fingerprint

Hemorrhage
Prednisolone
Therapeutics
Bleeding Time
Palmitates
Vital Capacity
Ferritins
Idiopathic pulmonary hemosiderosis
Bone Density
Dexamethasone
Steroids
Observation
Prospective Studies
Survival
Serum

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Long-term liposteroid therapy for idiopathic pulmonary hemosiderosis. / Doi, Takehiko; Ohga, Shoichi; ishimura, masataka; Takada, Hidetoshi; Ishii, Kanako; Ihara, Kenji; Nagai, Hideyuki; Hara, Toshiro.

In: European Journal of Pediatrics, Vol. 172, No. 11, 01.01.2013, p. 1475-1481.

Research output: Contribution to journalArticle

Doi, Takehiko ; Ohga, Shoichi ; ishimura, masataka ; Takada, Hidetoshi ; Ishii, Kanako ; Ihara, Kenji ; Nagai, Hideyuki ; Hara, Toshiro. / Long-term liposteroid therapy for idiopathic pulmonary hemosiderosis. In: European Journal of Pediatrics. 2013 ; Vol. 172, No. 11. pp. 1475-1481.
@article{f416b1c6a073441db8ba70e856004893,
title = "Long-term liposteroid therapy for idiopathic pulmonary hemosiderosis",
abstract = "Control of refractory bleeding in idiopathic pulmonary hemosiderosis (IPH) is challenging. Based on the effect of liposteroid (dexamethasone palmitate) for acute bleeding in two reported cases, the long-term utility was assessed in all nine IPH children (including the first two cases) treated in a tertiary center for 20 years. The median at disease onset was 2.3 years (range, 1.2 to 8.6). All had life-threatening and/or repetitive bleeding on prednisolone (PSL) therapy. Liposteroid was intravenously infused at 0.8 mg/kg/day for three consecutive days at the time of acute bleeding. Single infusion was followed by a longer interval from weekly to monthly accompanied by low-dose PSL (less than 0.3 mg/kg/day). Monthly infusion as maintenance therapy was continued for prophylaxis of bleeding. Treatment outcomes were retrospectively analyzed. During the observation period of a median of 11.0 years (range 2.4-16.9 years), no one died. Five patients were weaned and the other one was being weaned from liposteroid for the cure or long remission (median, 5.5 years). Three others were on liposteroid therapy because of active disease. Neither patient had respiratory symptoms, although three showed subnormal {\%}vital capacity. Serum levels of KL-6 and ferritin were normal in all and all but one patient(s), respectively. Four patients (three on liposteroid therapy) showed low bone mineral density. There were no obese patients. Height SD score did not significantly decrease except for one patient. Conclusion: The liposteroid therapy might improve the survival of IPH patients with reducing the adverse effects of steroids, although prospective control studies are needed.",
author = "Takehiko Doi and Shoichi Ohga and masataka ishimura and Hidetoshi Takada and Kanako Ishii and Kenji Ihara and Hideyuki Nagai and Toshiro Hara",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/s00431-013-2065-9",
language = "English",
volume = "172",
pages = "1475--1481",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Long-term liposteroid therapy for idiopathic pulmonary hemosiderosis

AU - Doi, Takehiko

AU - Ohga, Shoichi

AU - ishimura, masataka

AU - Takada, Hidetoshi

AU - Ishii, Kanako

AU - Ihara, Kenji

AU - Nagai, Hideyuki

AU - Hara, Toshiro

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Control of refractory bleeding in idiopathic pulmonary hemosiderosis (IPH) is challenging. Based on the effect of liposteroid (dexamethasone palmitate) for acute bleeding in two reported cases, the long-term utility was assessed in all nine IPH children (including the first two cases) treated in a tertiary center for 20 years. The median at disease onset was 2.3 years (range, 1.2 to 8.6). All had life-threatening and/or repetitive bleeding on prednisolone (PSL) therapy. Liposteroid was intravenously infused at 0.8 mg/kg/day for three consecutive days at the time of acute bleeding. Single infusion was followed by a longer interval from weekly to monthly accompanied by low-dose PSL (less than 0.3 mg/kg/day). Monthly infusion as maintenance therapy was continued for prophylaxis of bleeding. Treatment outcomes were retrospectively analyzed. During the observation period of a median of 11.0 years (range 2.4-16.9 years), no one died. Five patients were weaned and the other one was being weaned from liposteroid for the cure or long remission (median, 5.5 years). Three others were on liposteroid therapy because of active disease. Neither patient had respiratory symptoms, although three showed subnormal %vital capacity. Serum levels of KL-6 and ferritin were normal in all and all but one patient(s), respectively. Four patients (three on liposteroid therapy) showed low bone mineral density. There were no obese patients. Height SD score did not significantly decrease except for one patient. Conclusion: The liposteroid therapy might improve the survival of IPH patients with reducing the adverse effects of steroids, although prospective control studies are needed.

AB - Control of refractory bleeding in idiopathic pulmonary hemosiderosis (IPH) is challenging. Based on the effect of liposteroid (dexamethasone palmitate) for acute bleeding in two reported cases, the long-term utility was assessed in all nine IPH children (including the first two cases) treated in a tertiary center for 20 years. The median at disease onset was 2.3 years (range, 1.2 to 8.6). All had life-threatening and/or repetitive bleeding on prednisolone (PSL) therapy. Liposteroid was intravenously infused at 0.8 mg/kg/day for three consecutive days at the time of acute bleeding. Single infusion was followed by a longer interval from weekly to monthly accompanied by low-dose PSL (less than 0.3 mg/kg/day). Monthly infusion as maintenance therapy was continued for prophylaxis of bleeding. Treatment outcomes were retrospectively analyzed. During the observation period of a median of 11.0 years (range 2.4-16.9 years), no one died. Five patients were weaned and the other one was being weaned from liposteroid for the cure or long remission (median, 5.5 years). Three others were on liposteroid therapy because of active disease. Neither patient had respiratory symptoms, although three showed subnormal %vital capacity. Serum levels of KL-6 and ferritin were normal in all and all but one patient(s), respectively. Four patients (three on liposteroid therapy) showed low bone mineral density. There were no obese patients. Height SD score did not significantly decrease except for one patient. Conclusion: The liposteroid therapy might improve the survival of IPH patients with reducing the adverse effects of steroids, although prospective control studies are needed.

UR - http://www.scopus.com/inward/record.url?scp=84886779910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886779910&partnerID=8YFLogxK

U2 - 10.1007/s00431-013-2065-9

DO - 10.1007/s00431-013-2065-9

M3 - Article

C2 - 23812505

AN - SCOPUS:84886779910

VL - 172

SP - 1475

EP - 1481

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 11

ER -